Uridine 5′-diphospho-glucuronosyltransferases (UGTs) are involved in the metabolism of lamotrigine, but whether the UGT1A4 and UGT2B7 genetic polymorphisms affect lamotrigine concentration remains controversial. Thus, the objective of this meta-analysis was to analyse the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration. Through searching, screening, selection, data extraction and quantitative analyses, the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration-to-dose ratio 
| INTRODUCTION
Uridine 5′-diphospho-glucuronosyltransferases (UGTs) are major enzymes involved in the process of glucuronidation, a major contributor to drug metabolism. 1 Genetic polymorphisms in UGT isoenzymes (UGT1A4 70C>A, UGT1A4 142T>G, UGT2B7 -161C>T and UGT2B7 802C>T) have been documented as the most common genetic polymorphisms potentially influencing interindividual variability in drug metabolism. [2] [3] [4] Lamotrigine, an antiepileptic drug and a mood stabilizer, is primarily metabolized by UGT-mediated glucuronidation, which is the rate-limiting step in the removal of lamotrigine from the body. 5 High concentrations of lamotrigine are associated with adverse effects such as benign rash, gastrointestinal trouble and multi-organ failure associated with Stevens-Johnson syndrome. 6, 7 Since the concentration of lamotrigine is correlated strongly with tolerability, ensuring it is not too high is important. However, a high interindividual difference in lamotrigine concentration induced by polymorphic UGT makes it difficult to accurately control the concentration. This has led to many studies attempting to correlate changes in lamotrigine concentration with UGT genotype, and several studies suggest that UGT genetic polymorphisms strongly influence lamotrigine concentration. 8, 9 By contrast, other studies observed no significant differences in lamotrigine concentration according to UGT genotype.
These apparent discrepancies could be due to low sample sizes for each genotype and/or population heterogeneity. Meta-analysis has many advantages including increasing sample size by combining data derived from several studies, facilitating the derivation of more robust conclusions. Therefore, in the present work, we performed a meta-analysis to evaluate the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration.
| EXPERIMENTAL PROCEDURES

| Search strategy
Before this study, all processes of the meta-analysis were predetermined according to the checklist in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 12 Two researchers independently searched PubMed, EMBASE and Web of Science using search terms representing UGT1A4, UGT2B7 and lamotrigine. Additionally, relevant references mentioned within the selected articles were screened for inclusion. The search process was not restricted by publication language, and the most recent search was performed on 10 March 2018.
| Study selection
Two researchers each evaluated the searched articles for eligibility in the meta-analysis. Inclusion criteria were (a) analysis of UGT1A4 and UGT2B7 genetic polymorphisms (UGT1A4 70C>A, UGT1A4 142T>G, UGT2B7 -161C>T and UGT2B7 802C>T) in human being, (b) comparing concentration-to-dose ratio (CDR) according to the status of UGT genotypes, (c) reporting the sample size of each genotype and (d) reporting at least one of either the mean plus standard deviation, the median plus range or the mean plus P-value of the CDR. CDR was selected as the study outcome because a linear relationship has been documented between the dose and concentration of lamotrigine. Exclusion criteria were (a) studies that reported concentrations which were not adjusted for dose, (b) patients receiving medications which could interact with lamotrigine such as valproic acid, (c) review articles and case reports involving fewer than 10 patients (d) conference abstracts without available data and (e) studies with overlapping populations. In order to identify the net effects of UGT genotypes, possible interaction by co-administered medications was excluded.
Two researchers selected studies independently using EndNote X8 citation management software in two steps: (a) potential eligibility screening by reviewing titles and abstracts and (b) final selection for inclusion by reviewing the full text. The inconsistency of judgement concerning inclusion was resolved by discussion between the two authors.
| Data extraction and quality assessment
Data were extracted from the main text and tables of the included studies using a pre-prepared data extraction sheet. Study authors were contacted when unreported data needed to be clarified. Extracted information included the first author, year of publication, age of participants, regimen of lamotrigine therapy, UGT genotypes, sample size and statistical value of the CDR for each genotype.
The quality assessment process for the included studies was independently performed by two researchers, and discrepancies were resolved before data analysis. The Newcastle-Ottawa Scale was used to evaluate and assure the relative consistent quality among studies. 13 
| Statistical analysis
Quantitative analysis was conducted using Comprehensive Meta-Analysis version 3 software (CMA 3; BioStat Inc, Englewood, NJ, USA) and R program with the metaphor package. Heterogeneity across studies was evaluated using the Higgin's I 2 statistic (the percentage of variation across studies due to heterogeneity rather than chance) and Cochran's Q test. 14 For significant heterogeneity (I 2 > 50% or P < 0.10), the random effect model was used, and the fixed effect model was used otherwise. 15 Bayesian random-effects meta-analysis was used for meta-analysis of two studies in the presence of heterogeneity. 16 Non-informative uniform prior distribution was used for the parameter of interest (μ), and half-normal prior distribution with scale parameter 0.5 was used for the heterogeneity (τ). 16 The median and interquartile range were replaced by mean and standard deviation. Combined estimates of the magnitude of the effect were calculated as the standardized difference in means (SDM). Statistical tests were two-sided, and the results are described in forest plots. A P-value of <0.05 was considered statistically significant. Subgroup analyses were performed according to age group, where possible. Reporting bias detection through review of a funnel plot and additional sensitivity analysis were performed where possible.
| RESULTS
| Characteristics of the included studies
A total of 213 articles were obtained from electronic databases, and 119 articles remained after removal of duplicates. Through the two-step selection process represented in Figure 1 , seven studies were finally selected. Characteristics of the included studies are presented in Table 1 . 4, [8] [9] [10] [11] 17, 18 Two studies on UGT1A4 70C>A, five studies on UGT1A4 142T>G, two studies on UGT2B7 -161C>T and one study on UGT2B7 802C>T genetic polymorphisms were included. A study by Petrenaite et al evaluated lamotrigine concentrations before pregnancy, in the first, second and third trimester, and post-partum; thus, only data obtained before pregnancy were used in the analysis. Some patients included in Petrenaite et al received lamotrigine in combination with topiramate, levetiracetam or clonazepam. Because these co-administered drugs do not interact with lamotrigine, the study was considered eligible.
| UGT1A4 70C>A and 142T>G
The influence of UGT1A4 genetic polymorphisms on lamotrigine CDR values is shown in Figure 2 . Two studies with 119 patients compared CDR values between the UGT1A4 70C>A wild-type (WT) and heterozygous variants. There was no significant difference in CDR values between the UGT1A4 70C>A heterozygous variant and the WT (SDM = 0.433, 95% confidence interval [CI] = −0.380-1.302; Figure 2 ).
Five studies with 382 patients compared CDR values between the UGT1A4 142T>G WT and variants. UGT1A4 142T>G variants did not show a significant difference in CDR values (SDM = −0.458, 95% CI = −1.141-0.224; Figure 3 ). Subgroup analysis revealed that CDR values were not significantly different between UGT1A4 142T>G variants and WT in paediatric group (SDM = −0.122, 95% CI = −1.186-0.972; Figure 3 ). For the nonpaediatric group, UGT1A4 142T>G WT tended to have higher CDR values than variants, but the difference was not significant (SDM = −0.722, 95% CI = −1.546-0.102; Figure 3 ).
| UGT2B7 -161C>T and 802C>T
Two studies with 158 patients compared CDR values between the UGT2B7 -161C allele and the -161C>T homozygous variant. UGT2B7 -161C>T homozygous variant had significantly higher CDR values than the WT and heterozygous variant (SDM = 0.634, 95% CI = 0.056-1.222; Figure 4 ). The estimated mean CDR was 1.25 times greater in the homozygous variant than WT and heterozygous variant (1.438 ± 0.187 vs 1.151 ± 0.097 mg/L per mg/kg). In subgroup analysis of nonpaediatric population, UGT2B7 -161C>T homozygous variant tended to have higher CDR values than WT and heterozygous variant, but the difference was not significantly different (SDM = 1.022, 95% CI = −0.007-2.226; Figure 4 ). Only one study was carried out on the paediatric population, and thus, subgroup analysis was not possible. Sanchez et al reported that there was no significant difference in CDR values between the UGT2B7 -161C>T homozygous variants and the WT and heterozygous variant (0.72 ± 0.14 vs 0.77 ± 0.05 mg/ L per mg/kg) in paediatrics. Only one study with 40 patients reported CDR values for the UGT2B7 802C>T, and thus, meta-analysis was not conducted. The CDR values for UGT2B7 802CC, 802CT and 802TT were 0.051 ± 0.017, 0.054 ± 0.018 and 0.07 ± 0.031 μmol/L/mg, respectively.
| DISCUSSION
In this meta-analysis, the influence of UGT1A4 and UGT2B7 genetic polymorphisms on the CDR values of lamotrigine was evaluated. This approach has the advantage of increasing the chances of achieving reliable and integrated conclusions by combining the results from previous small-scale studies with relatively low sample size.
Concomitant medication has been known to be the most significant factor influencing interindividual variability in lamotrigine CDR values. 18 VPA is a well-known UGT inhibitor which can decrease lamotrigine clearance by 30.8%~52.8%. 19 On the other hand, hepatic enzyme-inducing anticonvulsants such as carbamazepine, phenytoin and phenobarbital can increase lamotrigine clearance and reduce lamotrigine CDR by 66%. 20 Therefore, combination therapy with valproic acid and enzyme-inducing drugs was excluded from this meta-analysis. This meta-analysis focused on the results of patients receiving neither valproic acid nor enzyme inducers to evaluate the net influence of UGT genetic polymorphisms. Meta-analysis showed that UGT2B7 -161C>T homozygous variants displayed significantly increased CDR values for lamotrigine. UGT2B7 -161C>T is a synonymous polymorphism within the promoter region; hence, it does not alter the amino acid sequence of the UGT2B7 enzyme, but it may affect the level of transcription of the gene encoding the enzyme. 21 In vitro analysis showed that the UGT2B7 -161C allele displayed a 2-times increase in transcriptional activity compared with the 161T allele. 22 This clinical result is in line with those of a previous in vitro study in which a homozygous variant of the UGT2B7 enzyme displayed decreased glucuronidation activity. As a result, CDR values were increased for the homozygous variant. These findings are in line with the population pharmacokinetic studies, which found that the UGT2B7 -161C>T affects the clearance of lamotrigine. 23, 24 In this meta-analysis, UGT1A4 70C>A and 142T>G did not have a significant impact on the lamotrigine CDR. Several in vitro studies demonstrated that UGT1A4 70C>A has no effect on UGT1A4 enzyme activity. [25] [26] [27] For UGT1A4 142T>G, in vitro studies showed conflicting results of unchanged, increased and decreased activity. 25, 26, 28 The effect of UGT1A4 142 > G genetic polymorphism on lamotrigine metabolism may not be strong enough to cause significant difference in CDR. Subgroup analysis according to age showed that the effects of the UGT1A4 142T>G and UGT2B7 -161C>T genetic polymorphisms on CDR values were observed only by trends in nonpaediatric populations but not in paediatric populations. There would have been little difference by genotype because the activity of UGT enzymes was significantly lower in children than in adults. 29, 30 Therefore, paediatric patients may not need to be considered for their genotype.
The findings of this study have various clinical implications. Firstly, at the clinical site, the lamotrigine dose can be gradually increased by monitoring adverse effects rather than measuring the drug concentration. Thus, proper use of lamotrigine is a difficult task for even the most experienced psychiatrists and neurologists. By the time adverse effects such as severe rash are visible, there has already been a dramatic drop in adherence to medication and a likely collapse in rapport between patients and physicians. 31, 32 In addition, fatal adverse effects such as Stevens-Johnson syndrome occur more frequently when the dose of medication is increased suddenly, rather than when a general titration schedule is followed. 33 It is difficult for clinicians to increase the lamotrigine dose in an outpatient setting, since it is impossible for close observation and immediate first aid treatment. Therefore, clinicians usually use extremely slow titration, but this strategy can delay the improvement of symptoms. The current results indicate the importance of UGT2B7 -161C>T genotyping prior to initiation of lamotrigine therapy, and indicate the potential for reducing the dose of initial lamotrigine by approximately 0.8-times in epilepsy patients harbouring the UGT2B7 -161C>T homozygous variant, relative to WT and heterozygous variant patients because of 1.25 times greater CDR. A patient-specific dosing strategy may therefore be helpful in clinical therapy. Adverse effects may be prevented in patients harbouring homozygous variants via slow titration and lower initial dose, whereas WT and heterozygous variant patients can be expected to display sufficient drug efficacy.
The present study has some limitations. Firstly, after filtering, the meta-analysis included a relatively small number of studies, which may lower the statistical power of the analysis. To compensate for this limitation, if there were two studies, conservative but interpretable results were drawn using the Bayesian random-effects meta-analysis. 16 Secondly, publication bias could not be evaluated because the number of included studies was less than 10. Thus, attention should be paid to the interpretation of meaningful results, and additional studies supporting the results are needed to allow a more reliable comparison of CDR values for lamotrigine based on UGT2B7 genotypes. In our opinion, more population pharmacokinetic studies need to be done in the future to estimate clearance, which is a more meaningful parameter, and to compensate for the impact of other factors.
In conclusion, CDR values of lamotrigine were found to be significantly higher for the UGT2B7 -161C>T homozygous variant than for WT and heterozygous variant patients.
